Scientific article

Treating pulmonary hypertension in pediatrics

Published inExpert opinion on pharmacotherapy, vol. 16, no. 5, p. 711-726
Publication date2015

Pulmonary hypertension is a hemodynamic condition occurring rarely in pediatrics. Nevertheless, it is associated with significant morbidity and mortality. When characterized by progressive pulmonary vascular structural changes, the disease is called pulmonary arterial hypertension (PAH). It results in increased pulmonary vascular resistance and eventual right ventricular failure. In the vast majority of cases, pediatric PAH is idiopathic or associated with congenital heart disease, and, contrary to adult PAH, is rarely associated with connective tissue, portal hypertension, HIV infection or thromboembolic disease.

  • Child
  • Drug Therapy, Combination
  • Endothelin Receptor Antagonists/therapeutic use
  • Epoprostenol/analogs & derivatives/therapeutic use
  • HIV Infections
  • Humans
  • Hypertension, Pulmonary/classification/drug therapy
  • Phosphodiesterase 5 Inhibitors/therapeutic use
  • Quality of Life
Citation (ISO format)
LADOR, Frédéric, SEKARSKI, Nicole, BEGHETTI, Maurice. Treating pulmonary hypertension in pediatrics. In: Expert opinion on pharmacotherapy, 2015, vol. 16, n° 5, p. 711–726. doi: 10.1517/14656566.2015.1013937
Main files (1)
Article (Published version)
ISSN of the journal1465-6566

Technical informations

Creation10/18/2015 3:36:00 PM
First validation10/18/2015 3:36:00 PM
Update time03/14/2023 11:44:11 PM
Status update03/14/2023 11:44:10 PM
Last indexation10/18/2023 11:56:17 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack